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Abstract 
Introduction 
Mantle cell lymphoma (MCL) is an uncommon subtype of lymphoid malig-
nancy with usually aggressive clinical behaviour. Rituximab (MabThera
®
) is 
a monoclonal antibody approved for the treatment of non-Hodgkin’s lym-
phoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis 
and granulomatosis with polyangiitis and microscopic polyangiitis. To date, 
neither the European Medicines Agency (EMA) nor the US Food and Drug 
Administration (FDA) have granted marketing authorisation for rituximab 
as maintenance therapy in patients with MCL after autologous stem-cell 
transplantation (ASCT).  
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer, resulting in 197 references overall. A quality 
assessment was conducted to assess the risk of bias at the study level based 
on the EUnetHTA internal validity for randomised controlled trials. The 
magnitude of clinically meaningful benefit that can be expected from a new 
anti-cancer treatment based on the Magnitude of Clinical Benefit Scale de-
veloped by the European Society for Medical Oncology (ESMO-MCBS) has 
not been applied since it can only be used for solid tumours. 
Results from the LyMa trial 
The LyMa trial was conducted to assess the efficacy and safety of rituximab 
maintenance therapy in MCL patients after ASCT. To this end, a total of 
299 patients who were younger than 66 years of age were enrolled, 240 of 
whom were randomly assigned to receive either rituximab maintenance 
therapy or to undergo observation. At the LyMa study stopping date (July 1, 
2015), the rate of event-free survival (EFS) at four years was 79% in patients 
of the rituximab maintenance group compared to 61% in patients of the ob-
servation group. At four years, patients of the rituximab maintenance group 
had a progression-free survival (PFS) rate of 83% versus 64% in observation 
group patients. The rate of overall survival (OS) at four years was higher in 
the rituximab group (89%) than in the observation group (80%). Median 
OS, PFS and EFS had not been reached. The most frequent adverse event 
(AE) of grade ≥3 in both groups within the first six months of treatment was 
neutropenia, occurring more often in the rituximab maintenance group 
(41.1%) than in the observation group (26.3%). Other frequent AEs of grade 
3–4 within the first six months were infections (6.3%) and thrombocytopenia 
(5.4%) in the rituximab maintenance group and thrombocytopenia (4.2%) 
and infections (3.4%) among patients in the observation group.  
Conclusion 
Although rituximab maintenance therapy provides essential benefits for pa-
tients with MCL after ASCT, relevant issues, including schedules of rituxi-
mab administration, the applicability of study results in older patients or 
patients with worse performance status, types of previously administered 
chemotherapeutical regimens, the role of MRD and, not least, the impact of 
rituximab maintenance therapy on QoL need to be clarified. Due to the 
small number of MCL-affected patients, gathering significant evidence 
might prove difficult. Anyhow, more data is warranted to confirm the results 
of the LyMa trial.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to predefined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is rituximab? 
A0022 Who manufactures rituximab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has rituximab received marketing authorisation? 
Health problem and current use 
A0002 What is mantle cell lymphoma? 
A0004 What is the natural course of mantle cell lymphoma? 
A0006 What are the consequences of mantle cell lymphoma for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of disease of mantle cell lymphoma? 
A0003 What are the known risk factors for mantle cell lymphoma? 
 
A0024 
How is mantle cell lymphoma currently diagnosed according to published guidelines and 
in practice? 
A0025 
How is mantle cell lymphoma currently managed according to published guidelines and 
in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect rituximab on mortality? 
D0006 How does rituximab affect progression (or recurrence) of mantle cell lymphoma? 
D0005 
How does rituximab affect symptoms and findings (severity, frequency) of mantle cell 
lymphoma? 
D0011 What is the effect of rituximab on patients’ body functions? 
D0012 What is the effect of rituximab on generic health-related quality of life? 
D0013 What is the effect of rituximab on disease-specific quality of life? 
Safety 
C0008 How safe is rituximab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying rituximab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of rituximab? 
A0021 What is the reimbursement status of rituximab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
Horizon Scanning in Oncology 
8 LBI-HTA | 2018 
2 Drug description 
Generic/Brand name/ATC code:  
Rituximab/MabThera
®
/‎L01XC02 
 
B0001: What is rituximab? 
Rituximab (MabThera
®
) is a monoclonal antibody targeting the CD20 anti-
gen which is located on normal pre-B and mature B lymphocytes. CD20 is 
found on both normal and malignant B cells and is expressed on >95% of 
all B-cell non-Hodgkin’s lymphomas (NHL). The binding of rituximab to 
the CD20 antigen triggers a host cytotoxic immune response against CD20-
positive cells. In detail, the antigen-binding fragment (Fab) domain of ritux-
imab binds to the CD20 antigen on B lymphocytes and the fragment crystal-
lisable (Fc) domain mediates B-cell lysis by recruiting immune effector 
functions. Possible mechanisms are complement-depending cytotoxicity and 
antibody-dependent cellular cytotoxicity. On B lymphocytes, the binding of 
rituximab to CD20 antigen induces cell death due to apoptosis [2, 3]. 
Rituximab is available as a concentrate for solution for infusion in vials con-
taining 100 mg of rituximab each; each mL contains 10 mg of rituximab. It 
is administered as an intravenous infusion (IV) through a dedicated line; it 
should not be given as an IV push or bolus. For the first infusion, the rec-
ommended initial rate is 50 mg/h which can be escalated after the first 30 
minutes in 50 mg/h increments every 30 minutes to a maximum of 400 
mg/h. For all indications, subsequent infusions can be given at an initial 
rate of 100 mg/h and increased by 100 mg/h increments every 30 minutes to 
a maximum of 400 mg/h [2]. 
In the phase III LyMa trial, the schedule for maintenance therapy was the 
administration of 375 mg of rituximab IV per square metre of body surface 
area every two months for three years [4]. 
Prior to the administration of rituximab, patients should receive premedica-
tion including an antipyretic and an antihistaminic. An administration of 
glucocorticoids should be considered in patients with NHL and chronic 
lymphocytic leukaemia (CLL) who do not receive rituximab in combination 
with glucocorticoid-containing therapy [2]. 
Patients who receive rituximab should be closely monitored for the onset of 
cytokine release syndrome [2], a large rapid release of cytokines into the 
blood causing fever, nausea, headache, rash, rapid heartbeat, low blood pres-
sure and breathing problems. Most patients experience a mild reaction, but 
severe or life-threatening reactions are possible [5]. In patients with a severe 
cytokine release syndrome, the infusion of rituximab should be interrupted 
immediately and aggressive symptomatic treatment should be administered 
[2]. 
 
A0022: Who manufactures rituximab? 
Roche Pharma AG (product licence holder) 
 
monoclonal antibody  
 
 
targeting the CD20 
antigen 
administered 
intravenously 
premedication: 
antipyretic, 
antihistaminic 
monitoring is required 
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3 Indication 
A0007: What is the target population in this assessment? 
Rituximab is indicated in patients with mantle cell lymphoma (MCL) af-
ter autologous stem-cell transplantation (ASCT). 
 
 
 
4 Current regulatory status 
A0020: For which indications has rituximab received marketing authorisa-
tion? 
To date, neither the European Medicines Agency (EMA) nor the US Food 
and Drug Administration (FDA) have granted marketing authorisation for 
rituximab as maintenance therapy in patients with MCL after ASCT.  
The EMA approved rituximab (MabThera
®
) for the following indications 
[6]: 
 The treatment of previously untreated patients with stage III–IV 
follicular lymphoma (FL) in combination with chemotherapy 
 As maintenance therapy in patients with FL who respond to induc-
tion therapy 
 As monotherapy for the treatment of patients with stage III–IV FL 
who are chemo-resistant or are in their second or subsequent re-
lapse after chemotherapy 
 In combination with CHOP (cyclophosphamide, doxorubicin, vin-
cristine, prednisolone) chemotherapy in patients with CD20-
positive diffuse large B-cell NHL 
 In combination with chemotherapy for the treatment of patients 
with previously untreated and relapsed/refractory CLL 
 In combination with methotrexate for the treatment of adult pa-
tients with severe active rheumatoid arthritis who have had an in-
adequate response or intolerance to other disease-modifying anti-
rheumatic drugs including one or more tumour-necrosis-factor 
(TNF) inhibitor therapies 
 In combination with glucocorticoids for the induction of remission 
in patients with severe, active granulomatosis with polyangiitis 
(Wegener’s) (GPA) and microscopic polyangiitis (MPA). 
In April 2017, the EMA granted orphan designation for rituximab for treat-
ment in solid organ transplantation [6]. 
In the US, the FDA approved rituximab (trade name: Rituxan
®
) for the 
treatment of [7]: 
 Relapsed or refractory, low-grade or follicular, CD20-positive B-cell 
NHL (as a single-agent) 
 Patients with previously untreated follicular, CD20-positive B-cell 
NHL in combination with first-line chemotherapy and, in patients 
patients with MCL after 
ASCT 
currently not approved 
for maintenance 
therapy in patients with 
MCL after ASCT, but for 
several other indications 
approved indications of 
rituximab in the US 
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achieving a complete or partial response (PR) to rituximab in com-
bination with chemotherapy, as single-agent maintenance therapy 
 Non-progressing (including stable disease), low-grade, CD20-
positve B-cell NHL as a single agent after first-line cyclophospha-
mide, vincristine and prednisolone (CVP) chemotherapy 
 Previously untreated diffuse large B-cell, CD20-positive NHL in 
combination with CHOP or other anthracycline-based chemother-
apy regimens 
 In combination with fludarabine and cyclophosphamide for the 
treatment of patients with previously untreated and previously 
treated CD20-positive CLL 
 in combination with methotrexate for the treatment of adult pa-
tients with moderately to severely active rheumatoid arthritis who 
have had an inadequate response to one or more TNF antagonist 
therapies 
 Patients with GPA and MPA. 
 
 
 
5 Burden of disease 
A0002: What is mantle cell lymphoma? 
MCL is a subtype of NHL and is thought to have two different cellular ori-
gins leading to different forms of the disease [8]:  
The “classical” MCL arises from naïve B cells (about 80% of MCL cases) 
that express SOX11 (a transcription factor) and involves lymph nodes and 
extranodal sites, e.g. the gastrointestinal tract. Due to acquisition of addi-
tional genetic abnormalities, a progression to more aggressive forms of MCL 
with blastoid or pleomorphic morphologies is possible. The other variant of 
MCL (termed “leukaemic” variant), developing from antigen-experienced 
SOX11-negative B cells, often spares lymph nodes and mainly affects the pe-
ripheral blood, bone marrow and spleen. Although this type of MCL often 
appears clinically indolent, secondary abnormalities (particularly TP53 mu-
tations) can cause a very aggressive course [8]. Cytologically, four types of 
MCL are defined, including the small-cell variant, the mantle-zone variant, 
the diffuse variant and the blastic variant [9]. 
 
A0004: What is the natural course of mantle cell lymphoma? 
The course of MCL is variable [8] and the clinical behaviour is usually ag-
gressive [10]. At the time of diagnosis, most patients have advanced disease 
[8], only a few patients present with localised disease [11]. The overall 5-year 
survival rate for advanced-stage MCL is about 50%, in patients with limited-
stage MCL about 70% [12]. 
The blastoid type of MCL is deemed to be more aggressive. Although, pa-
tients without anaemia or splenomegaly, patients with a normal serum-free 
light-chain ratio or patients with tumour cells not overexpressing cyclin D, 
may show longer survival. As reported in several studies, patients aged >60 
MCL: uncommon  
NHL subtype 
 
 
 
“classical” and 
“leukaemic” variant 
variable course, usually 
aggressive 
blastoid MCL type is 
considered more 
aggressive 
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with an increased mitotic index or patients with an increased Ki-67 staining 
were associated with significantly worse overall survival [8]. 
The most commonly used prognostic indices for MCL are the International 
Prognostic Index (IPI), the Follicular Lymphoma International Prognostic 
Index (FLIPI) and the Mantle Cell Lymphoma International Prognostic In-
dex (MIPI). All of these indices comprise information about the age of the 
patient, the lactate dehydrogenase (LDH) level and the stage of the disease, 
varying in the way of incorporation of information about nodal involvement, 
performance status and blood counts [8]. The MIPI is the prognostic index 
most commonly used, incorporating ECOG performance status, age, leuko-
cyte count and LDH [9]. MIPI is particularly suited for patients with MCL 
and allows a classification of patients into low-risk, intermediate-risk and 
high-risk groups, helping to facilitate risk-adapted treatment decisions in 
patients affected by advanced stage MCL [13].  
 
A0006: What are the consequences of mantle cell lymphoma for the society? 
A0023: How many people belong to the target population? 
MCL is an uncommon subtype of lymphoid malignancy, representing 5% to 
7% of malignant lymphoma in Western Europe with an annual incidence of 
1–2/100,000. MCL is more common in men than in women (3:1 ratio) [14]; 
the median age at MCL diagnosis is 68 years [8]. In 2015, a total of 1,318 
persons were newly diagnosed with NHL in Austria. The age-standardised 
incidence rate for the European Standard Population (2015, newly diag-
nosed NHL cases) is 18.8 per 100,000 per year in men and 12.7 per 100,000 
per year in women [15].  
 
A0005: What are the symptoms and the burden of disease of mantle cell 
lymphoma? 
The majority of patients with MCL (approximately 75%) typically present 
with lymphadenopathy, the remaining 25% of patients present with extran-
odal disease. Commonly affected sites include the lymph nodes, spleen, 
Waldeyer’s ring, bone marrow, blood and extranodal sites such as the gastro-
intestinal tract (where the manifestations occasionally present as lympho-
matous intestinal polyposis), breast, pleura and orbit [8].  
Systemic B symptoms are shown by up to one third of patients and include 
fever (temperature >38 °C), night sweats (drenching) and unintentional 
weight loss (>10% of body weight over the past six months). In patients with 
the “leukaemic” variant of MCL, lymph nodes are often spared and leukae-
mic presentations predominate; a common symptom is splenomegaly in the 
absence of lymphadenopathy. Affection of the central nervous system occurs 
in <5% of MCL cases, but is more common in the SOX11-negative variant 
of MCL [8, 16]. 
 
A0003: What are the known risk factors for mantle cell lymphoma? 
According to Wang et al. [12], the development and progression of MCL is a 
complex process that includes the joint effects of multiple families of risk 
factors and their interactions. Only a few potential risk factors have been 
validated; however, their clinical use has been limited. 
prognostic indices: MIPI, 
IPI, FLIPI 
MCL:  
5–7% of malignant 
lymphoma 
 
median age at diagnosis: 
68 years 
 
75% of MCL patients 
present 
lymphadenopathy 
approximately  
1/3 of patients have B 
symptoms 
multiple risk factors but 
limited clinical use 
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A0024: How is mantle cell lymphoma currently diagnosed according to pub-
lished guidelines and in practice? 
In patients with suspected MCL, the diagnosis should be based on a tissue 
biopsy [8], preferably obtained from a lymph node [14]. In patients with 
leukaemic manifestations only, a bone marrow biopsy could be sufficient if 
additional diagnostic measures are used [14]. Immunohistochemistry should 
be applied to evaluate the involvement of cyclin D1. Karyotyping or fluores-
cence in situ hybridisation can be useful to detect the t(11;14) (q13;32) trans-
location [8] which is the molecular hallmark of MCL that can be shown in 
most MCL cases and identifies the disease [9].  
For the staging of MCL, the following diagnostic measures should be ap-
plied: a complete blood count, chemistry profile, LDH level, a bone marrow 
evaluation (with immunophenotyping flow cytometry of the bone marrow 
and blood) and computed tomography (CT) of the chest, abdomen and pel-
vis or fluorodeoxyglucose-positron emission tomography (FDG-PET/CT). 
Depending on the presence of clinical symptoms, an endoscopy of the gas-
trointestinal tract (which is also applied if a dose-intense regimen will be 
used) or evaluation of the cerebral spin fluid (in case of neurologic symp-
toms, or if the patient has the blastoid variant or a high Ki-67) can be ap-
plied [9]. 
The Ann Arbor staging system, first published in 1971 and extended by the 
“Cotswold modifications” in 1989 has been originally developed for the stag-
ing of Hodgkin lymphoma but is also used for the staging of NHL. A more 
recent classification system is the Lugano classification, published in 2014 
[17]. 
According to the Lugano classification, 4 stages of MCL are defined [14]: 
 Stage I (I
E
): 1 lymph node or extranodal site (I
E
) is involved 
 Stage II (II
E
): 2 or more lymph node regions or localised extranodal 
sites (II
E
) on the same side of the diaphragm are involved 
 Stage III: lymph node regions or lymphoid structures (e.g. thymus, 
Waldeyer’s ring) on both sides of the diaphragm are involved 
 Stage IV: diffuse or disseminated extralymphatic organ involve-
ment. 
In situ mantle cell neoplasia, CLL, follicular lymphoma, marginal zone 
lymphoma (nodal or extranodal), lymphoblastic lymphoma [8] and diffuse 
large B-cell lymphoma (DLBCL) should be considered for differential diag-
nosis. 
 
 
 
6 Current treatment 
A0025: How is mantle cell lymphoma currently managed according to pub-
lished guidelines and in practice? 
The National Comprehensive Cancer Network (NCCN) [11] recommends 
the following treatment options for MCL, based on the clinical stage of the 
disease:  
diagnosis based on 
tissue biopsy 
 
 
t(11;14) (q13;32) is a 
hallmark of MCL 
diagnostic measures  
for staging  
 
 
4 stages of MCL are 
defined by the Lugano 
classification 
differential diagnosis 
NCCN treatment 
recommendations 
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For the first-line therapy and follow-up of stage I-II MCL, the NCCN rec-
ommends – outside of a clinical trial – radiotherapy (RT) with 30–36 Gy 
alone or a combination of immunochemotherapy with or without RT. 
For the initial induction therapy of stage II (bulky) and stage III–IV disease, 
the panel included the following regimens for aggressive therapy: 
 Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexa-
methasone) + rituximab 
 Dose-intensified CHOP (cyclophosphamide, doxorubicin, vincris-
tine, prednisone) (maxi-CHOP) alternating with rituximab + high-
dose cytarabine (NORDIC regimen) 
 Rituximab and methotrexate with augmented CHOP (CALGB reg-
imen) 
 Sequential R-CHOP (rituximab, cyclophosphamide, doxorubicin, 
vincristine, prednisone) and R-ICE (rituximab, ifosfamide, car-
boplatin, etoposide) 
 Alternating R-CHOP and R-DHAP (rituximab, dexamethasone, 
cisplatin, cytarabine). 
All of those regimens (except for hyper-CVAD + rituximab) include first-
line consolidation with high-dose therapy followed by autologous stem-cell 
rescue (HDT/ASCR). For patients who are in remission after first-line ther-
apy with R-CHOP and are not eligible for HDT/ASCR, maintenance treat-
ment with rituximab, administered every eight weeks until disease progres-
sion, is recommended [11]. However, rituximab is not yet approved for this 
indication either in Europe or in the US. 
For less aggressive therapy in patients with stage II (bulky) and stage III–IV 
disease, recommended regimens include: 
 Bendamustine + rituximab 
 Bortezomib, rituximab, cyclophosphamide, doxorubicin and pred-
nisone (VR-CAP) 
 Cladribine + rituximab 
 R-CHOP 
 Modified Hyper-CVAD with rituximab maintenance in patients 
older than 65 years. 
The optimal treatment for patients with relapsed or refractory disease still 
needs to be defined. Patients who experience relapse following complete re-
mission (CR) to induction therapy, patients who obtain only partial remis-
sion to induction therapy or patients with progressive disease are appropri-
ate candidates to participate in clinical trials. If no appropriate clinical trial 
is available, those patients can receive second-line chemotherapy regimens 
(with or without rituximab) recommended for patients with diffuse large B-
cell lymphoma. Alternatively, the following regimens are recommended for 
these patients as second-line chemotherapy: 
 Bendamustine ± rituximab 
 Bortezomib ± rituximab 
 Cladribine ±rituximab 
 FC (Fludarabine, cyclophosphamide) ± rituximab 
 FCMR (Fludarabine, cyclophosphamide, mitoxantrone, rituximab) 
1st-line and follow-up 
treatment (stages I–II) 
aggressive treatment 
options (stage II and 
stages III–IV) 
less aggressive 
treatment options 
(stage II and stages III–
IV) 
optimal therapy for 
relapsed or refractory 
MCL not defined 
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 FMR (Fludarabine, mitoxantrone, rituximab) 
 Lenalidomide ± rituximab 
 PCR (pentostatin, cyclophosphamide, rituximab) 
 PEPC (prednisone, etoposide, procarbazine, cyclophosphamide) ± 
rituximab. 
In patients with relapsed or refractory disease that is in remission after sec-
ond-line therapy, an allogeneic transplantation is an appropriate therapeuti-
cal option.  
 
 
 
7 Evidence 
A literature search was conducted on 11 January 2018 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “rituximab”, “MabThera”, “mantle cell lymphoma”, and 
“maintenance therapy”. Also, the manufacturer was contacted, who submit-
ted 14 references (5 of them had already been identified by systematic litera-
ture search) and results from a literature search and a list of complet-
ed/ongoing clinical trials. A manual search identified 31 additional refer-
ences (web documents and journal articles). 
Overall, 197 references were identified. Included in this report are:  
 LyMa, a phase III study assessing rituximab maintenance therapy 
in mantle cell lymphoma patients after ASCT [4] 
 A double-randomised intergroup trial assessing the efficacy and 
safety of a fludarabine-containing induction regimen and rituximab 
maintenance therapy [18]  
 A phase III study of the German Low Grade Lymphoma Study 
Group investigating rituximab maintenance therapy after rituxi-
mab-containing chemotherapy for relapsed MCL and FL [19] 
 2 retrospective studies [20, 21] and one analysis [22]. 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [23]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patients and treating physicians, selec-
tive outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 (see appendix). 
The external validity of the included trials was assessed using the EU-
netHTA guideline on applicability of evidence in the context of a relative ef-
fectiveness assessment of pharmaceuticals, considering the following ele-
ments: population, intervention, comparator(s), outcomes and setting [24]. 
systematic literature 
search in 5 databases:  
165 hits 
 
manual search: 32 
additional references 
 
overall: 197 references 
included: 5 studies, 1 
analysis 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
external validity 
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The evaluation of the magnitude of “clinically meaningful benefit” that can 
be expected from a new anti-cancer treatment, the Magnitude of Clinical 
Benefit Scale developed by the European Society for Medical Oncology 
(ESMO-MCBS), was been applied, since it can only be used for solid tu-
mours [25]. 
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III study 
The LyMa trial, a randomised, prospective phase III trial, was conducted to 
assess the role of rituximab maintenance therapy in patients with MCL who 
had undergone ASCT [4, 26, 27]. From September 2008 to August 2012, a to-
tal of 299 patients younger than 66 years of age were enrolled, 240 of whom 
were randomised to either the rituximab maintenance group (n = 120) or 
the observation group (n = 120). Included patients had a median age of 58 
(rituximab maintenance group) and 56 (observation group) years and were 
predominantly male. All patients had untreated MCL, Ann Arbor stage II–
IV disease, were eligible for ASCT and had an Eastern Cooperative Oncolo-
gy Group (ECOG) performance status score of less than 3.58% (rituximab 
maintenance), and 52% (observation group) of patients had a low risk MIPI 
score. In both groups, 35% of patients had more than 30% of Ki-67-positive 
cells. Detailed patient characteristics including inclusion and exclusion cri-
teria can be found in Table 4. 
Patients were included in the trial at the time of diagnosis and received four 
courses of R-DHAP, repeated every 21 days as an induction chemotherapy 
magnitude of clinically 
meaningful benefit 
based on ESMO-MCBS 
couldn’t be assessed 
internal and 
external review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
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(investigators were also allowed to use carboplatin or oxaliplatin instead of 
cisplatin). Only patients having a CR and those with a PR whose tumour 
mass was reduced by ≥75% after the induction therapy, were eligible to un-
dergo transplantation. After four courses of R-DHAP, the overall response 
rate (ORR) was 89% and the complete response rate (CRR) was 77%. Pa-
tients having a PR and patients whose tumour mass had been reduced by 
<75% received a rescue induction therapy with four courses of R-CHOP 
every two weeks.  
Prior to transplantation, patients received R-BEAM as conditioning regi-
men, consisting of rituximab, carmustine, etoposide, cytarabine and melpha-
lan. A total-body radiation was not applied to reduce the risk of long-term 
effects. Of 299 enrolled patients, 257 patients underwent transplantation; 
65% of those patients had a CR and 24% had an unconfirmed CR. The me-
dian time from ASCT to randomisation was 2.1 months in either group. Pa-
tients assigned to the rituximab maintenance group received 375 mg of 
rituximab per square metre of body surface area, given IV every two months 
for three years. In the rituximab maintenance group, a total of 83 patients 
completed the scheduled 3-year course of treatment.  
The primary endpoint of the LyMa study was event-free survival (EFS) after 
four years from randomisation with events defined as disease progression, 
relapse, death, severe infection (grade 4 with life-threatening severity) or al-
lergy to rituximab leading to treatment discontinuation after randomisation. 
Secondary endpoints were progression-free survival (PFS) including free-
dom from disease progression, relapse and death from any cause, overall 
survival (OS) defined as the period from the date of randomisation to the 
date of death from any cause. Further secondary endpoints were CRR, PR 
and ORR, measured after induction and after ASCT. Hospitalisations, all 
toxicities, all adverse events (AEs), all serious AEs (SAEs) and all deaths 
(listed and summarised by cause of death) were defined as safety endpoints. 
The LyMa study stopping date was July 1, 2015; median follow-up from in-
clusion was 54.4 months, median follow-up from randomisation was 50.2 
months. Clinical efficacy data of the LyMa trial are presented in Table 1 and 
AEs are listed in Table 2. 
 
7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of rituximab on mortality? 
OS was a secondary endpoint of the LyMa trial. With 89% (95% CI 81–94), 
the 4-year rate of OS was statistically significantly higher in patients of the 
rituximab maintenance group compared with 80% (95% CI 72–88) in pa-
tients of the observation group with a hazard ratio (HR) for death of 0.50 
(95% CI 0.26–0.99; p = 0.04). 
Median OS was reached neither in the overall patient population nor in any 
subgroup except for high-risk patients (56.2 months, p < 0.001, as compared 
with the low-risk group). The 4-year rate of OS among patients of the in-
cluded patient population was 78% (95% CI, 73–82). 
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D0006: How does rituximab affect progression (or recurrence) of mantle cell 
lymphoma? 
The primary endpoint of the LyMa trial was EFS after four years; median 
EFS from randomisation was not reached in either group. The 4-year rate of 
EFS calculated from randomisation was 79% (95% CI 70–86) in patients of 
the rituximab group compared to 61% (95% CI 51–70) in patients of the ob-
servation group (p = 0.001), with a HR for disease progression, relapse, 
death, rituximab allergy or severe infection of 0.46 (95% CI 0.28–0.74; p = 
0.002). 21% of rituximab maintenance group patients had an event (accord-
ing to protocol definition) compared to 39% of observation group patients. 
PFS was a secondary endpoint of the present phase III study and was not 
reached in the included patient population as calculated from inclusion; the 
4-year rate of PFS among these patients was 68% (95% CI 62–73). Median 
PFS was not reached among low-risk and intermediate-risk patients, where-
as median PFS in high-risk patients was 47.4 months. With 83% (95% CI 
73–88), the 4-year rate of PFS was significantly higher in patients receiving 
rituximab maintenance therapy compared to 64% (95% CI 55–73) in the ob-
servation group (HR for disease progression, relapse or death, 0.40; 95% CI 
0.23–0.68; p < 0.001). 
 
D0005: How does rituximab affect symptoms and findings (severity, fre-
quency) of mantle cell lymphoma? 
No evidence was found to answer this research question. 
 
D0011: What is the effect of rituximab on patients’ body functions? 
No evidence was found to answer this research question. 
 
D0012: What is the effect of rituximab on generic health-related quality of 
life? 
D0013: What is the effect of rituximab on disease-specific quality of life? 
No evidence was found to answer these research questions as neither health-
related quality of life (HRQoL) nor quality of life (QoL) were endpoints of 
the present study. 
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Table 1: Efficacy results of the LyMa trial [4] 
Descriptive statistics 
and estimate  
variability 
Treatment group Rituximab Observation 
Number of patients 120 120 
EFS 
median EFS, months 
4-year EFS rate, % (95% CI) 
 
NR 
79 (70–86) 
 
NR 
61 (51–70) 
PFS 
median PFS, months 
4-year PFS rate, % (95% CI) 
 
NR 
83 (73–88) 
 
NR 
64 (55–73) 
OS 
median OS, months 
4-year OS rate, % (95% CI) 
 
NR 
89 (81–94) 
 
NR 
80 (72–88) 
QoL NA NA 
Effect estimate per 
comparison 
 
Comparison groups Rituximab maintenance 
vs. observation 
4-year EFS rate HR1  0.46 
95% CI 0.28–0.74 
Log-rank test p value 0.002 
4-year PFS rate  HR2 0.40 
95% CI  0.23–0.68 
Log-rank test p value < 0.001 
4-year OS rate HR3 0.50 
95% CI 0.26–0.99 
Log-rank test p value 0.04 
Abbreviations: CI = confidence interval, EFS = event-free survival, HR = hazard ratio, NA = not available, NR = not 
reached, OS = overall survival, PFS = progression-free survival, QoL = quality of life, 
1 
= HR for disease progression, 
relapse, death, rituximab allergy or severe infection, 
2 
= HR for disease progression, relapse or death,
 3 
= HR for death 
 
 
 
7.2.2 Safety 
 
C0008: How safe is rituximab in relation to the comparator(s)? 
The most common grade 3 and 4 AE was neutropenia. Within the first six 
months, 41.1% of patients of the rituximab maintenance group and 26.3% of 
observation group patients experienced neutropenia. Other frequent AEs of 
grades 3–4 within the first six months were infections (6.3%) and thrombo-
cytopenia (5.4%) in the rituximab maintenance group and thrombocytope-
nia (4.2%) and infections (3.4%) among patients in the observation group. 
Death due to second cancer occurred in three patients of the rituximab 
maintenance group and in one patient in the observation group. 
Grade 1–2 toxicities that occurred after transplantation were infections (126 
events in 80 patients in the rituximab maintenance group, 67 events in 54 
patients in the observation group) and neutropenia (92 events in 35 patients 
in the rituximab maintenance group, 45 events in 29 patients in the observa-
tion group). No late effects of rituximab maintenance therapy were reported. 
neutropenia: most 
frequent AE of grade >3 
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The most frequent reasons for discontinuation of rituximab maintenance 
treatment were disease progression and neutropenia. In four patients of each 
group, a serious infection after transplantation occurred, including spondy-
litis, pyelonephritis, septicaemia and varicella pneumonia in rituximab 
maintenance group patients; septicaemia, cellulitis, meningitis and severe 
pneumonia in observation group patients. 
No calculation of statistical significance was applied for safety parameters. 
 
C0002: Are the harms related to dosage or frequency of applying rituximab? 
No evidence was found to answer this research question. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of rituximab? 
During pregnancy, rituximab should only be used if the mother’s potential 
benefit justifies the potential risk of the foetus, as postmarketing data indi-
cates that B-cell lymphocytopenia (generally lasting <6 months) can occur 
in infants who were exposed to rituximab in utero. Rituximab was detected 
postpartum in the serum of infants who were exposed in utero. There is no 
data available as to whether rituximab is secreted into human milk [7]. 
 
 
Table 2: LyMa trial: Grade 3 and 4 toxicities [27] 
 
Adverse Event 
(Intensity of AEs rated 
by using NCI-CTC 
criteria) 
 
Intervention  Control  
 <6 months 
n = 112 
n (%) 
6–12 months 
n = 102 
n (%) 
12–36 months 
n = 99 
n (%) 
<6 months 
n = 118 
n (%) 
6–12 months 
n = 110 
n (%) 
13–36 months 
n = 104 
n (%) 
Haematology (all) 51 (45.5) 25 (24.5) 22 (22.2) 44 (37.3) 14 (12.7) 26 (25.0) 
Neutropenia 46 (41.1) 16 (15.7) 12 (12.1) 31 (26.3) 1 (0.9) 3 (2.9) 
Thrombocytopenia 6 (5.4) 4 (3.9) 5 (5.1) 5 (4.2) 2 (1.8) 4 (3.8) 
Infections classified as 
an event 
1 (0.9) 1 (1.0) 2 (2.0) 1 (0.8) 1 (0.9) 2 (1.9) 
Infections 7 (6.3) 2 (2.0) 3 (3.0) 4 (3.4) 2 (1.8) 3 (2.9) 
Cutaneous 0 (0.0) 0 (0.0) 2 (2.0) 1 (0.8) 0 (0.0) 1 (1.0) 
GI function 1 (0.9) 1 (1.0) 1 (1.0) 1 (0.8) 0 (0.0) 0 (0.0) 
Pulmonary function 1 (0.9) 1 (1.0) 2 (2.0) 3 (2.5) 1 (0.9) 4 (3.8) 
Cardiac function 0 (0.0) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0) 1 (1.0) 
Neurology 4 (3.6) 2 (2.0) 4 (4.0) 0 (0.0) 2 (1.8) 1 (1.0) 
Transaminases 5 (4.5) 4 (4.0) 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Bilirubin 1 (0.9) 1 (1.0) 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 
Creatinine 2 (1.8) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Abbreviations: AE = adverse event, GI = gastrointestinal, n = number, NCI = National Cancer Institute, CTC = common toxicity 
criteria 
disease progression and 
neutropenia most 
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treatment 
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7.3 Clinical effectiveness and safety –  
further studies 
There is no further study available that has investigated rituximab mainte-
nance therapy in patients with MCL after ASCT. 
Kluin-Nelemans et al. [18] conducted a double-randomised trial assessing 
two objectives, comparing the response rates of R-FC (rituximab, fludara-
bine and cyclophosphamide) induction regimen to the application of R-
CHOP in patients not eligible for high-dose therapy. Patients who had a re-
sponse were randomised again to maintenance therapy with rituximab or in-
terferon alfa. A total of 485 patients at a median age of 70 years and predom-
inantly male were included in the primary analysis of response; 274 patients 
were randomised to receive either rituximab at 375 mg/m
2
 every two months 
or standard interferon alfa at a dose of three million units three times per 
week, given until disease progression. Analysis showed that CR rates were 
similar in both R-FC (40%) and R-CHOP (34%), p = 0.10. In patients re-
ceiving R-FC, progressive disease occurred more often (14% vs. 5% with R-
CHOP), OS was statistically significantly shorter (47% vs. 62% after four 
years) and more patients died during the first remission. The frequency of 
grade 3 or 4 infections was balanced between the two groups; haematological 
toxic effects occurred more often in patients receiving R-FC. The primary 
analysis of maintenance therapy showed a risk reduction of progression or 
death by 45% in patients receiving rituximab compared to the patients re-
ceiving interferon alfa (HR 0.55; 95% CI, 0.36–0.87; p = 0.01). After four 
years, 58% of patients who received rituximab were in remission versus 29% 
of patients who received interferon alfa. In patients showing a response to R-
CHOP who received rituximab maintenance therapy, the OS after four years 
was statistically significantly improved: the 4-year survival rate was 87% 
compared to 63% with interferon alfa, p = 0.005. 
However, a prospective, randomised, open-label multicentre phase III study 
of the German Low Grade Lymphoma Study Group (GLSG) [19] investigat-
ed rituximab maintenance therapy after rituximab-containing chemothera-
py in patients with recurring and refractory FL and MCL. 195 patients with 
a median age of 62 years, all having advanced stage III or IV disease were in-
cluded. 58% of patients had FL, 34% had MCL and 8% of patients had oth-
er lymphoma subtypes; all patients had received at least one type of chemo-
therapy before. The patients were randomly assigned to receive four courses 
of fludarabine, cyclophosphamide and mitoxantrone (FCM) alone or in 
combination with rituximab (R-FCM). Patients responding to the treatment 
were randomised again for rituximab maintenance therapy; they received 
two courses (each course consisting of four doses of 375 mg/m
2
/day given for 
four consecutive weeks) of rituximab given three and nine months after 
completion of salvage therapy. Patients assigned to the observation group 
received no further treatment. After 147 patients, randomisation was 
stopped due to the fact that R-FCM revealed a statistically significantly bet-
ter outcome; hence, all subsequent patients received R-FCM. Analyses 
showed that the duration of response was significantly prolonged in patients 
receiving rituximab maintenance therapy after R-FCM compared to the ob-
servation group. Median survival was not reached in either study arm; the 
estimated proportion of patients alive at three years was 77% after rituximab 
maintenance therapy versus 57% in the observation group. 
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Graf et al. [20] conducted a retrospective study in 157 MCL patients who 
underwent ASCT to investigate the benefit of rituximab maintenance thera-
py. The median age of the patients was 57 years, 85% of patients were male. 
32% of patients received different maintenance rituximab regimens (a me-
dian of 8 doses of rituximab was administered at a dose of 375 mg/m
2
); 68% 
of patients did not receive rituximab maintenance therapy. 92% of patients 
received rituximab before ASCT; transplant conditioning was radiation 
based in 78% of patients. Rituximab maintenance treatment started at a 
median of 77 days after ASCT. After a median follow-up of five years after 
ASCT, analyses showed that the administration of rituximab was associated 
with a statistically significantly improved PFS (HR 0.44; 95% CI 0.24-0.80, p 
= 0.007) and an improved OS (HR 0.46; 95% CI 0.23–0.93, p = 0.03) com-
pared to patients not receiving rituximab maintenance therapy. 34% of 
rituximab maintenance therapy patients had grade 4 neutropenia, compared 
to 18% in patients not receiving rituximab (p = 0.04). 32% of patients re-
ceived granulocyte colony stimulating factor for neutropenia in the rituxi-
mab maintenance group versus 12% in patients without rituximab mainte-
nance therapy (p = 0.005). 
191 MCL patients treated with ASCT were included in a singlecentre retro-
spective study [21] to assess the effectiveness of maintenance rituximab 
therapy. At the time of diagnosis, the median age of patients was 59 years, 
74% of patients were male and nearly all of the patients had stage III–IV 
disease. 67% of patients had received one frontline therapy prior to ASCT; 
56% received a high-dose cytarabine containing frontline treatment. For 
conditioning therapy prior to ASCT, 53% of patients received chemotherapy 
only, 47% underwent radiation-based conditioning regimens. The majority 
of patients received rituximab prior to ASCT, 39% of patients received 
rituximab maintenance after ASCT. Rituximab maintenance therapy was 
administered in 3 different dosing schedules. 5-year PFS was 53% (95% CI: 
45%–60%) and OS was 71% (95% CI: 63%–77%) for patients receiving 
ASCT. The 5-year cumulative incidence of relapse was 41% (95% CI: 34%–
48%) with a total of 83 relapses occurring at a median of 2.1 years (ranging 
from 0.2 to 13.4). Rituximab maintenance therapy after ASCT was signifi-
cantly associated with superior PFS and OS; the benefit of rituximab 
maintenance therapy was assessed in all age groups. The most common 
cause of non-relapse mortality in study patients was secondary cancer in 7%. 
An analysis in 72 patients to evaluate the outcome for MCL patients after 
ASCT conducted by Dietrich et al. [22] is only available in form of an ab-
stract. MCL patients receiving rituximab maintenance therapy after ASCT 
in a phase II trial were compared with patients who had undergone ASCT 
but did not receive rituximab maintenance. A total of 72 patients with a me-
dian age of 60 years were included; 22 patients participated in the phase II 
trial and were randomised to receive rituximab maintenance therapy after 
ASCT. All patients received rituximab prior to the ASCT; high-dose cytara-
bine (HD-ARA-C) was administered in 45 patients. ASCT was performed in 
51 patients after administering first-line treatment; 27 patients achieved CR 
before ASCT. The median observation time after ASCT was 56 months. PFS 
after two years was 90% in the rituximab maintenance group compared to 
65% in the control group. Two-year OS was 88% in the rituximab mainte-
nance group versus 80% in the control group. Univariate analysis showed a 
significantly better PFS in the patients receiving rituximab maintenance 
(HR 0.21; p = 0.014). The beneficial effect of rituximab maintenance thera-
py (HR 0.23; p = 0.02) was also shown by multivariate adjustment for age 
(HR per year 0.98; p = 0.79), year of transplant (HR per calendar year 1.0; p 
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= 0.96), achievement of CR prior to ASCT (HR 1.59; p = 0.26), upfront 
ASCT (HR 0.81; p = 0.80) and HD-ARA-C treatment (HR 0.69; p = 0.63). 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of rituximab? 
Rituximab (MabThera
®
) is available as a concentrate for solution for infu-
sion in vials of 100 mg (one package contains two vials) at € 613.45 (ex-
factory price) and 500 mg at € 1,516.43 [28]. 
In the LyMa trial, patients received 375 mg of rituximab per square metre of 
body surface area, given intravenously every two months for three years. The 
total number of planned rituximab doses was 23, comprising 18 doses ad-
ministered every other month for three years as trial medication, four doses 
as induction therapy and one dose given with the preparative regimen for 
transplantation [4]. Assuming a body surface area of 1.73 m
2
, costs for one 
dose (649 mg) of rituximab are approximately € 2,129.90 (using two vials of 
100 mg and one vial of 500 mg). According to the LyMa trial schedule with a 
total of 23 doses of rituximab (induction therapy + preparative regimen for 
ASCT + three years of maintenance therapy) a total course of rituximab 
maintenance therapy costs approximately € 48,987.70. 
 
 
 
9 Ongoing research 
In February, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted. The following phase III studies, 
evaluating the use of rituximab maintenance therapy in MCL, were identi-
fied: 
 NCT01933711: An open-label, prospective, randomised phase III 
trial to evaluate rituximab maintenance therapy versus observation 
in patients with aggressive CD20-positive B-cell lymphoma and 
MCL. The estimated study completion date is December 2018. 
 NCT01996865: A multicentre, open-label phase III trial (MAGNI-
FY) of lenalidomide plus rituximab followed by lenalidomide ver-
sus rituximab maintenance in patients with relapsed/refractory fol-
licular lymphoma, marginal zone lymphoma or MCL. Estimated 
study completion date is March 2023. 
 NCT00209209 (EudraCT Number: 2005-005375-15): A phase III, 
open-label randomised study (MCLelderly) investigating two inde-
pendent questions in the MCL treatment of elderly patients. One 
aim of the trial is to investigate whether rituximab plus a combina-
tion of fludarabine with cyclophosphamide results in a higher re-
duction of lymphoma mass than rituximab combined with the 
costs for 1 dose of 
rituximab: approx.  
€ 2,129.90 
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standard chemotherapy scheme; the second aim is to evaluate if 
maintenance with rituximab can substitute the interferon mainte-
nance and even improve PFS in patients after successful initial cy-
toreductive therapy. Estimated study completion date is December 
2018. 
 NCT01865110 (EudraCT Number: 2012-002542-20): A randomised, 
open-label phase III trial evaluating the efficacy of alternating im-
munochemotherapy (consisting of R-CHOP + R-HAD versus R-
CHOP alone, followed by maintenance therapy consisting of addi-
tional lenalidomide + rituximab versus rituximab alone) in pa-
tients ≥60 years with MCL. Estimated study completion date is 
March 2024. 
 NCT03267433: A randomised, open-label phase III study evaluat-
ing rituximab with or without stem-cell transplant in patients with 
minimal residual disease-negative MCL in first complete remis-
sion. Estimated study completion date is January 2032. 
 NCT00877214: A randomised, open-label phase III trial investigat-
ing the significance of extended rituximab maintenance therapy in 
follicular lymphomas and the significance of rituximab mainte-
nance therapy in other indolent and mantle cell lymphomas com-
pared to observation. Estimated study completion date is April 
2022. 
There are several phase II trials investigating the role of rituximab mainte-
nance therapy in MCL in different settings and combinations with other 
drugs: 
 NCT02633137: A phase II study evaluating sequential chemothera-
py and lenalidomide followed by rituximab and lenalidomide 
maintenance in MCL patients. Estimated study completion date is 
December 2018. 
 NCT00878254: A phase II trial investigating rituximab in combina-
tion with methotrexate, doxorubicin, cyclophosphamide, leuco-
vorin, vincristine, ifosfamide, etoposide, cytarabine and mesna in 
previously untreated MCL patients. Estimated study completion 
date is December 2019. 
 NCT01267812: A phase II study of bortezomib and rituximab 
maintenance therapy (weekly administration) in patients with 
MCL who have previously undergone hematopoietic stem-cell 
transplantation. Estimated study completion date is July 2018. 
 NCT01472562: A phase II multicentre trial evaluating the efficacy 
and safety of first-line lenalidomide + rituximab in patients with 
previously untreated MCL. Estimated study completion date is Oc-
tober 2020.  
 NCT01665768: A phase II study investigating rituximab mainte-
nance therapy with mTor inhibition (by everolimus) after high-dose 
consolidative therapy in CD20+, B-cell lymphomas, gray zone 
lymphoma and Hodgkin’s lymphoma. Estimated study completion 
date is July 2020.  
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10 Discussion 
Rituximab (MabThera
®
) is a monoclonal antibody approved for the treat-
ment of NHL, CLL, rheumatoid arthritis and granulomatosis with polyan-
giitis and microscopic polyangiitis. To date, rituximab has not received 
marketing authorisation either by the EMA or the FDA for the maintenance 
therapy in patients with MCL who have undergone ASCT.  
The LyMa trial [4] was conducted to assess the efficacy and safety of rituxi-
mab maintenance therapy in MCL patients after ASCT. Analyses showed a 
prolonged EFS rate of 18 percentage points at four years: the EFS rate was 
79% in patients of the rituximab maintenance group compared to 61% in 
patients of the observation group. The benefit of rituximab maintenance 
treatment has also been confirmed regarding PFS and OS results: at four 
years, patients of the rituximab maintenance group had a PFS rate of 83% 
versus 64% in observation group patients. The rate of OS at four years was 
higher in the rituximab group (89%) than in the observation group (80%). 
However, median OS, PFS and EFS were not reached. 
The most frequent AE of grade >3 in both groups within the first six months 
of treatment was neutropenia, occurring more often in the rituximab 
maintenance group (41.1%) than in the observation group (26.3%). Neutro-
penia was the reason for discontinuation of the study treatment in nine pa-
tients among the rituximab maintenance group. However, the rate of neu-
tropenia declined in the course of further treatment to 12.1% in rituximab 
maintenance group patients and 2.9% in the observation group patients af-
ter 12–36 months of treatment. At the time of final analysis, no late effects 
were reported in either group.  
Although maintenance therapy with rituximab seems to be well tolerated by 
the majority of patients and rates of AEs declined in the course of treatment, 
the occurrence of late effects is not determined. Although no late effects of 
rituximab maintenance therapy were reported at the time of final analysis of 
the LyMa trial, their subsequent occurrence cannot be ruled out. Further-
more, even though the LyMa trial showed beneficial effects of rituximab 
maintenance therapy for EFS, PFS and OS, median values for these study 
endpoints were not reached. Neither is any data available regarding patients’ 
quality of life (QoL). 
The external and internal validity of the LyMa trial is compromised by 
methodological limitations. The LyMa trial is an open-label study; both the 
patients and the treating physicians were unmasked to treatment assign-
ment. Furthermore, no information about the adequate generation of ran-
domisation sequence or adequate allocation concealment was available. In 
addition, the effect estimates for the comparison of rituximab maintenance 
therapy versus observation show wide confidence intervals (CIs), indicating 
great variability. However, a high risk of bias could be detected due to the 
open-label, unblinded study design, the lack of information about the gener-
ation of randomisation sequence and allocation concealment, and other as-
pects increasing the risk of bias.  
The patients included in the LyMa trial had a median age of 58 years in the 
rituximab maintenance group and 56 years in the observation group respec-
tively. Study patients had a good performance status, more than 50% of 
them had a low-risk MIPI score and 35% of patients had more than 30% of 
Ki-67-positive cells. As the general median age of MCL patients at the time 
rituximab: currently not 
approved for the 
assessed indication 
LyMa trial: prolongation  
at 4 y: 
+ 18% EFS 
+ 19% PFS 
+ 9% OS  
most frequent AE of 
grade >3: neutropenia 
median values for EFS, 
PFS and OS not reached 
 
 
no QoL data available 
high risk of bias: 
open-label study, no 
info on the generation 
of randomisation 
sequence and the 
allocation concealment  
 
wide CIs 
applicability of results in 
older and more diseased 
patients questionable 
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of diagnosis is 68 years, the study population was substantially younger. 
Thus, the applicability of the study results for older patients, patients with 
worse performance status and the consideration of risk factors needs to be 
clarified, particularly considering their eligibility for ASCT. Nevertheless, 
maintenance therapy may also be a relevant issue for patients who did not 
receive ASCT for any reason.  
LyMa trial patients received both R-DHAP, a rituximab-containing induc-
tion chemotherapy, and R-BEAM, a rituximab-containing conditioning reg-
imen before ASCT. It is unclear whether the beneficial effects of rituximab 
maintenance treatment are reproducible if other treatment regimens for in-
duction chemotherapy and/or conditioning therapy are used. However, 
Kluin-Nelemans et al. [18] showed significantly improved OS in patients re-
ceiving rituximab maintenance therapy after R-CHOP induction therapy, 
even though study patients did not receive ASCT. 
A further issue warranting investigation is the schedule of rituximab admin-
istration. A study [29] comparing rituximab maintenance therapy adminis-
tered every two months with rituximab maintenance every three months 
showed that patients in the every-2-months cohort were 3.4 times more like-
ly to experience toxicities. In addition, patients receiving rituximab more 
frequently showed a trend for shorter PFS, resulting from more dose delays 
or omissions and early treatment discontinuation. Hence, the optimal fre-
quency of rituximab application has yet to be determined. In addition, the 
ideal treatment length needs to be identified, since 83 of the 120 patients in 
the LyMa trial who received rituximab maintenance therapy, completed the 
3-year-course of treatment. In light of this fact, the subsequent therapy for 
these patients beyond three years must be determined. 
To select those patients who will benefit most from rituximab maintenance 
treatment, the minimal residual disease (MRD), which is defined as the 
minimal traceable persistence of lymphoma cells after successful treatment, 
can provide an early prediction of the recurrence of disease [30]. The clinical 
role of MRD analysis in MCL includes four major aspects: the prediction of 
disease recurrence, risk stratification, an early feedback on the efficacy of 
new treatment and personalised, pre-emptive medicine. There are several 
ongoing prospective clinical trials investigating the impact of MRD on the 
outcome of patients with MCL [31]. 
The costs for one dose of rituximab are approximately € 2,129.9 (ex-factory 
price) [28]. For a 3-year-course of rituximab maintenance therapy, as inves-
tigated in the LyMa trial, a total of 18 doses will be administered costing 
€ 38,338.2. Additionally, costs for rituximab-containing induction chemo-
therapy and the preparative regimen for transplantation (comprising anoth-
er five doses of rituximab) would incur, resulting in a total amount of 
€ 48,987.7. 
In 2017, the EMA granted marketing authorisation for two rituximab bio-
similars, Truxima
®
 (in February 2017) and Rixathon
®
 (in June 2017). Both 
rituximab biosimilars were approved for the same therapeutic indications as 
MabThera
® 
[32, 33]. In the U.S., the FDA accepted a biologics licence appli-
cation for Rixathon
®
 in September 2017 [34]. To date, no cost information is 
available for Austria for rituximab biosimilars. However, comparing the 
costs for MabThera
®
 with Truxima
®
 in Germany, the potential for cost sav-
ing is approximately 20% [35]. Price reductions for biosimilars are expected 
to range from 20% to 40% and potential cost savings of € 50–100 billion are 
forecasted by 2020 throughout Europe [36]. Since biosimilar medicines are 
approved according to the same standards regarding pharmaceutical quality, 
questionable impact of 
prior treatment 
regimens  
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MRD for early 
prediction of recurrence 
approx. € 48,987.70 for 
3 years of rituximab 
maintenance 
 
 
rituximab biosimilars 
approved in Europe 
 
 
 
cost-effective 
alternative 
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safety and efficacy applying to all biological medicines [37], they may pro-
vide a cost-effective alternative.   
Although rituximab maintenance therapy provides essential benefits for pa-
tients with MCL after ASCT, relevant issues, including schedules of rituxi-
mab administration, the applicability of study results in older patients or 
patients with worse performance status, types of previously administered 
chemotherapeutical regimens, the role of MRD and, not least, the impact of 
rituximab maintenance therapy on QoL need to be clarified. Due to the 
small number of MCL-affected patients, gathering significant evidence may 
prove to be difficult. However, more data is needed to confirm the results of 
the LyMa trial.  
rituximab maintenance 
treatment provides a 
benefit in young and fit 
patients  
 
lack of data on QoL 
 
optimal schedule needs 
to be determined 
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12 Appendix  
Table 3: Administration and dosing of rituximab [2] 
 Technology Comparator 
Administration mode Intravenous infusion (IV) 
No active compara-
tor is available 
Description of packaging 
 
Clear Type I glass vials with butyl rubber stopper contain-
ing 100 mg of rituximab in 10 mL. Packs of 2 vials. 
 
Total volume contained in packaging for sale 
 
MabThera 100  
mg concentrate for solution for infusion  
MabThera 500  
mg concentrate for solution for infusion  
MabThera 1400  
mg solution for subcutaneous injection  
MabThera 1600  
mg solution for subcutaneous injection  
 
Dosing 
LyMa trial: 375 mg of rituximab (IV) per square metre of 
body surface area, every 2 months for 3 years 
Median treatment duration - 
Contraindications 
For the use in NHL and CLL: 
 Hypersensitivity to the active substance or 
to murine proteins, or to any of the other 
excipients  
 Active, severe infections 
 Patients in a severely immunocompromised 
state 
For the use in rheumatoid arthritis: 
 Granulomatosis with polyangiitis and mi-
croscopic polyangiitis 
 Hypersensitivity to the active substance or 
to murine proteins, or to any of the other 
excipients 
 Active, severe infections 
 Patients in a severely immunocompromised 
state 
 Severe heart failure (New York Heart Asso-
ciation Class IV) or severe, uncontrolled 
cardiac disease 
Drug interactions 
To date, limited data on possible drug interactions are 
available  
 Patients with HAMA or HACA titres may have 
allergic or hypersensitivity reactions when 
treated with other diagnostic or therapeutic 
monoclonal antibodies. 
 In patients with rheumatoid arthritis, 283 pa-
tients received subsequent therapy with a bio-
logic DMARD following rituximab. In these pa-
tients, the rate of clinically relevant infection 
while receiving rituximab was 6.01 per 100 pa-
tient years compared to 4.97 per 100 patient 
years following treatment with the biologic 
DMARD. 
Abbreviations: CLL = chronic lymphocytic leukaemia, DMARD = disease-modifying anti-rheumatic drug, HAMA = hu-
man anti-mouse antibody, HACA = human anti-chimeric antibody, IV = intravenous 
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Table 4: Characteristics of the LyMa trial [4, 26, 27] 
Title: Rituximab after autologous stem-cell transplantation in mantle cell lymphoma [4, 26, 27] 
Study identifier NCT00921414, EudraCT number 2007-004644-70, LyMa  
Design Multicentre, open-label, randomised phase III study 
Duration of main phase: Enrolment: September 2008 to August 2012 
Median length of follow-up from inclusion: 54.4 months 
Median length of follow-up from randomisation: 50.2 
months 
Stopping date: July 1, 2015 
Hypothesis 
Superiority 
 
The study was designed to evaluate whether rituximab maintenance therapy after ASCT would 
prolong the duration of response in patients with mantle cell lymphoma. The total sample of 299 
patients provided the trial with 80% power to detect a difference of 13 percentage points in the 
rate of event-free survival at 4 years at an alpha level of 0.05. O’Brien-Fleming boundaries were 
used to check for type I error. Time-to-event survival curves were estimated by using the Kaplan 
Meier method. Time-to-event endpoints in the different groups were compared with the use of 
log-rank tests and Cox proportional hazards regression. Response rates were expressed in percent-
age with 95% exact confidence intervals that were based on the Clopper-Pearson method. All sta-
tistical analyses were performed using SAS software, version 9.3.  
Funding Roche and Amgen 
Treatment groups 
 
Intervention (n = 120) 
After ASCT, rituximab maintenance therapy was adminis-
tered at a dose of 375 mg (IV) per square metre of body 
surface area every 2 months for 3 years. Prior to ASCT, pa-
tients received induction chemotherapy with four courses 
of R-DHAP, repeated every 21 days. 
The conditioning regimen before ASCT was R-BEAM. 
Control (n = 120) 
After ASCT, patients underwent observation. Prior to 
ASCT, patients received induction chemotherapy with four 
courses of R-DHAP, repeated every 21 days.  
The conditioning regimen before ASCT was R-BEAM. 
Endpoints and definitions 
 
 
4-year event-free 
survival (primary 
endpoint) 
 
 
EFS 
EFS of patients who underwent ASCT and were random-
ised to one of the two arms of the protocol. Events were 
defined as disease progression, relapse, death, severe in-
fection (grade 4 with life-threatening severity) or allergy 
to rituximab that led to discontinuation of treatment after 
randomisation). EFS was determined by using the Kaplan 
Meier method). 
 
4-year progres-
sion-free survival 
(secondary end-
point) 
PFS 
Period from the date of randomisation to the date of first 
documented disease progression, relapse, or death from 
any cause. 
Assessed by using the Kaplan Meier method.  
 
4-year overall 
survival (second-
ary endpoint) 
 
OS 
 
Period from the date of randomisation to the date of 
death from any cause. 
Complete re-
sponse rate (sec-
ondary endpoint) 
CRR 
Assessed after induction and after ASCT on local assess-
ment, based on the International Workshop to Standardise 
Response Criteria for NHL for evaluation of response in 
Non-Hodgkin’s lymphoma (Cheson, 1999). 
 
Partial response 
rate (secondary 
endpoint) 
PR 
Assessed after induction and after ASCT. Patients without 
response assessment were considered as non-responders. 
 
Overall response 
rate (secondary 
endpoint 
ORR 
Assessed after induction and after ASCT. Patients without 
response assessment were considered as non-responders. 
 
Safety endpoints - 
Including hospitalisations, all toxicities (infections, haema-
tological, general), AEs of special interest, all SAEs, all 
deaths. 
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Title: Rituximab after autologous stem-cell transplantation in mantle cell lymphoma [4, 26, 27] 
Study identifier NCT00921414, EudraCT number 2007-004644-70, LyMa  
 
Exploratory end-
points - 
Including EFS, OS, EFS and PFS on 18 FDG-TEP/TDM, 
prognostic factors (IPI, MIPI, GOELAMS prognostic fac-
tors), MRD, detection of tumour makers, tumour bank 
(with tumour tissue, marrow and blood samples, serum). 
 
Database lock July 1, 2015 
Results and Analysis  
 
Analysis description 
 
Interim analysis was performed when at least 82 patients had reached 3 years after ASCT.  
Included patients set (IPS), includes all patients who signed the consent regardless of the study 
drug being received or not; set used for secondary objectives. 
Intention to treat set (ITT), includes all patients randomised, used for primary and secondary objec-
tives. 
Safety set (SS), includes all patients who received at least one dose of treatment. 
 
Analysis population   
Inclusion 
 MCL CD20-positive according to WHO 2008 classification 
 Untreated MCL patients older than 18 and younger than 66 
 At least one measurable site 
 ECOG performance status 0-1-2 
 Ejection cardiac function >50% 
 Signed informed consent 
 Measurable disease that requires treatment 
 Absolute neutrophil count >1.0 x 109/L 
 Platelets >50 x 109/L 
 AST and/or ALT <3 x ULN 
 Calculated creatinine clearance >50mL/min 
 Bilirubin <2 x normal 
 No other cancer (except in situ or baso-cellular) 
 
Exclusion 
 Other entity of lymphoma 
 Active HBV, HCV 
 HIV-positive 
 Active systemic infection requiring treatment 
 Uncontrolled diabetes 
 Patient unable to receive one drug in the treatment plan 
 
Characteristics 
 
 
Intervention 
(n = 120) 
 
 
Control 
(n = 120) 
Median age, years (range) 
Male sex, n (%) 
58 (27–65) 56 (29–65) 
92 (77) 97 (81) 
Ann Arbour stage, n/total n (%) 
    II 
    III 
    IV 
 
7/119 (6) 
15/119 (13) 
97/119 (82) 
 
5/120 (4) 
16/120 (13) 
99/120 (82) 
B-symptoms, n (%) 37 (31) 27 (22) 
ECOG performance status score <3, n (%) 117 (98) 113 (94) 
Bone marrow involvement, n (%) 76 (63) 73 (61) 
Lactate dehydrogenase >ULN, n (%) 33/118 (28) 46/118 (39) 
MIPI score, n (%) 
    Low risk 
    Intermediate risk 
    High risk 
 
70 (58) 
34 (28) 
16 (13) 
 
63 (52) 
31 (26) 
26 (22) 
Percent of Ki-67-positive cells >30%, n/total n (%) 32/92 (35) 29/83 (35) 
Variant mantle cell lymphoma n/total n (%) 
    On local review 
         Blastoid 
         Pleomorphic 
     On central review 
         Blastoid 
         Pleomorphic 
 
 
12/120 (10) 
1/120 (1) 
 
2/95 (2) 
10/95 (11) 
 
 
12/119 (10) 
5/119 (4) 
 
5/80 (6) 
11/80 (14) 
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Title: Rituximab after autologous stem-cell transplantation in mantle cell lymphoma [4, 26, 27] 
Study identifier NCT00921414, EudraCT number 2007-004644-70, LyMa  
R-CHOP before ASCT, n (%) 4 (3) 7 (6) 
 Disease status, n (%) 
     After receipt of 4 courses of R-DHAP 
        OR 
        Complete remission or unconfirmed complete   remission 
     After ASCT 
        OR 
        Complete remission or unconfirmed complete remission 
 
 
119 (99) 
102 (85) 
 
120 (100) 
113 (94) 
 
 
117 (98) 
104 (87) 
 
120 (100) 
110 (92) 
Time from ASCT to randomisation, months 
     Median  
     Range 
 
2.1 
0.4–4.2 
 
2.1 
0.4–3.9 
Applicability of evidence 
Population The LyMa trial included patients (18–65 years) with untreated MCL, who had disease of Ann Arbor 
stage II–IV, ECOG performance status score <3 and eligibility for ASCT.  
Intervention 
Rituximab is not yet approved for the maintenance therapy after ASCT, the indication assessed in 
the LyMa trial. The schedule for maintenance therapy in LyMa was the administration of 375 mg of 
rituximab (IV) per m2 of body surface area every 2 months for 3 years, with a planned total number 
of 23 rituximab doses (4 doses induction therapy, 1 dose with preparative regimen for transplanta-
tion and 18 doses over 3 years). 
Comparators Currently there is no data available comparing rituximab to another drug in this special setting (pa-
tients with untreated MCL after ASCT). 
Outcomes 
There is evidence that rituximab maintenance therapy prolongs EFS, PFS and OS; however, there is 
neither long-term data nor data on QoL available. 
As the general median age of diagnosis of MCL is 68 years, the applicability of the results needs to 
be clarified given the young age of the study population (median age was 56 years in the rituximab 
maintenance group and 58 years in the observation group respectively). 
Setting 
The LyMa trial is a multicentre study sponsored by the GOELAMS group and performed by the 
GOELAMS and GELA centres, now LYSA (The Lymphoma Study Association) for lymphoma studies. 
66 French investigator centres participated. 
Abbreviations: AE = adverse event, ALT = alanine transaminase, ASCT = autologous stem-cell transplantation, AST = aspartate transaminase, 
CRR = complete response rate, ECOG = Eastern Cooperative Oncology Group, EFS = event-free survival, HBV = hepatitis B virus , HCV = 
hepatitis C virus, IPI = International Prognostic Index, IPS = included patients set, ITT = intention to treat, LYSA = Lymphoma Study 
Association, MCL = mantle cell lymphoma, MIPI = Mantle Cell Lymphoma International Prognostic Index, n = number, OS = overall survival, 
OR = overall response, ORR = overall response rate, PFS = progression-free survival, PR = partial response, QoL = Quality of life , R-DHAP= 
rituximab, dexamethasone, high-dose cytarabine, cisplatin, R-BEAM = rituximab, carmustine, etoposide, cytarabine, melphalan, SS = safety set, 
ULN = upper limit normal, WHO = World Health Organization 
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Table 5: Risk of bias assessment on study level is based on EUnetHTA (internal validity of randomised controlled trials) [23] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: no information available Unclear 
Adequate allocation concealment: no information available Unclear 
Blinding: 
Patient: open-label No 
Treating physician: open-label No 
Selective outcome reporting unlikely: efficacy outcomes reported as described in protocol; 
withdrawals and drop-outs were reported 
Yes 
No other aspects which increase the risk of bias: sponsor supplied rituximab for the R-BEAM 
regimen and for maintenance therapy and funded the trial 
No 
Risk of bias – study level High 
Abbreviations: R-BEAM = rituximab, carmustine, etoposide, cytarabine, melphalan 
